China Pharma Holdings (CPHI) Total Liabilities (2010 - 2026)

China Pharma Holdings has reported Total Liabilities for 17 years, with the latest figure at $8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 12.04% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.1 million (up 12.04% YoY), and the FY2025 full-year result was $8.3 million, up 15.69% from the prior year.
• Total Liabilities for Q1 2026 stood at $8.1 million, down from $8.3 million in the prior quarter.
• The five-year high for Total Liabilities was $15.7 million in Q1 2022, with the low at $6.9 million in Q2 2024.
• Historically, Total Liabilities has averaged $9.8 million across 5 years, with a median of $8.3 million in 2025.
• Annual changes were most pronounced in 2022 — Total Liabilities advanced 23.83% — and 2024, when it plunged 39.63%.
• China Pharma Holdings' Total Liabilities stood at $13.5 million in 2022, then slumped by 33.2% to $9.0 million in 2023, then retreated by 20.8% to $7.1 million in 2024, then advanced by 15.69% to $8.3 million in 2025, then dropped by 1.7% to $8.1 million in 2026.
• The last three Total Liabilities figures came in at $8.1 million (Q1 2026), $8.3 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.